Emergency #medicine and internal medicine trainees’ smartphone use #mHealth

Purpose: Smartphone technology offers a multitude of applications (apps) that provide a wide range of functions for healthcare professionals. Medical trainees are early adopters of this technology, but how they use smartphones in clinical care remains unclear. Our objective was to further characterize smartphone use by medical trainees at two US academic institutions, as well as their prior…

A comparison of the BICAMS and the brief repeatable battery in #MultipleSclerosis #Neurology

Background

Recently, a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) has been developed as an international and standardized brief cognitive test, which is easily performed in everyday clinical practice for neuropsychological assessment in multiple sclerosis (MS). However, we need to gather more information about this tool compared to other neuropsychological batteries.…

Use of Accelerometers to Measure Physical Activity in Individuals with #MultipleSclerosis #mHealth

Background: Multiple sclerosis (MS) may negatively affect individuals’ participation in physical activity (PA). We used accelerometers to determine PA level in individuals with MS with varying degrees of disability as measured by the Expanded Disability Status Scale (EDSS) during regular daily activities.

Methods: Participants wore an accelerometer from 8 a.m. to 9 p.m. for 7 consecutive days.…

#Neurology Use of quantitative susceptibility mapping (QSM) in progressive multifocal leukoencephalopathy

Background

Progressive multifocal leukoencephalopathy (PML) is an opportunistic demyelinating encephalopathy related to JC virus. Its characteristics on conventional brain MRI are well known and are important for the diagnosis.

Objective

To analyze SWI hypointensities recently described in U-fibers and cortex adjacent to the white matter lesions of PML.

Methods

Prospective study including four…

#Neurology TYSABRI for Secondary Progressive #MultipleSclerosis Fails to Meet Phase 3 Trial Endpoints

“While we’re disappointed with these results, we believe this research will provide the MS community important insights into this more advanced patient population, and the benefits that natalizumab may provide in areas such as upper limb function,” said Dr. Alfred Sandrock, MD, group senior vice president and chief medical officer at Biogen, in a press release. 

via MultipleSclerosisNewsToday

No evidence for higher risk of cancer in patients with #multiplesclerosis taking cladribine #Neurology

Objective:

To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS).

Methods:

Meta-analysis of phase III trials of licensed DMDs for pwRMS and a phase III trial of cladribine (CLARITY). Cancer rates were compared using Fisher exact test.

Results:

Eleven trials were included. Investigated treatments…

ResearchKit is a pipeline for future diagnostic medical apps #hcsm #medsm #mHealth

“One way to think about ResearchKit is as the beginning of a pipeline that will lead to more apps that are screening, diagnostic, management and treatment apps,” Bud Tribble, MD, PhD, Vice President of Software Technology at Apple said. “In fact, it is a necessary, essential first step to figure out what is needed to develop these apps — what works and what doesn’t — before you move into,…